Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Immunology

Interleukin 12 Primes Macrophages for Nitric Oxide Production in Vivo and Restores Depressed Nitric Oxide Production by Macrophages from Tumor-bearing Mice: Implications for the Antitumor Activity of Interleukin 12 and/or Interleukin 2

Jon M. Wigginton, Douglas B. Kuhns, Timothy C. Back, Michael J. Brunda, Robert H. Wiltrout and George W. Cox
Jon M. Wigginton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas B. Kuhns
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy C. Back
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Brunda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H. Wiltrout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George W. Cox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published March 1996
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Interleukin-12 (IL-12) is a recently described immunoregulatory cytokine with potent therapeutic activity in various preclinical models of infectious or malignant disease. As part of our ongoing evaluation of potential mechanisms accounting for the potent antitumor activity of IL-12, we have investigated the influence of IL-12 administration on total serum nitrate/nitrite (NOx-) levels and the production of nitric oxide (NO) by peritoneal macrophages from normal and tumor-bearing mice. We report here that IL-12 administration to either normal or tumor-bearing mice for periods of time ranging from 7–19 days induced progressive increases in serum NOx- levels and primed peritoneal macrophages for NO production on subsequent exposure to lipopolysaccharide or IL-2 ex vivo. Treatment of resident peritoneal macrophages or the macrophage cell line ANA-1 with IL-12 alone or IL-12 in combination with various other stimuli failed to induce NO production, suggesting that the effects of IL-12 occurred via an indirect mechanism. Furthermore, we have shown that not only was the production of NO by macrophages from untreated long-term, tumor-bearing mice suppressed compared with control mice treated with vehicle or IL-12, but also that IL-12 administration overcame this suppression and delayed tumor growth. Lastly, we have shown that administration of weekly pulses of IL-2 in combination with IL-12 additively enhanced the priming of macrophages for NO production ex vivo and delayed tumor growth far more effectively than either agent alone. These observations and reports in the literature regarding the potential influence of NO on development of the immune response and on the regulation of tumor growth and vascularization suggest that NO may play a significant role in the antitumor activity of IL-12 and IL-2.

Footnotes

  • ↵1 To whom requests for reprints should be addressed, at In Vivo Biotherapy Section, Biological Carcinogenesis and Development Program, National Cancer Institute-FCRDC, Building 560, Room 31-93, Frederick, MD 21701-1201.

  • Received November 13, 1995.
  • Accepted December 21, 1995.
  • ©1996 American Association for Cancer Research.
PreviousNext
Back to top
March 1996
Volume 56, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Interleukin 12 Primes Macrophages for Nitric Oxide Production in Vivo and Restores Depressed Nitric Oxide Production by Macrophages from Tumor-bearing Mice: Implications for the Antitumor Activity of Interleukin 12 and/or Interleukin 2
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Interleukin 12 Primes Macrophages for Nitric Oxide Production in Vivo and Restores Depressed Nitric Oxide Production by Macrophages from Tumor-bearing Mice: Implications for the Antitumor Activity of Interleukin 12 and/or Interleukin 2
Jon M. Wigginton, Douglas B. Kuhns, Timothy C. Back, Michael J. Brunda, Robert H. Wiltrout and George W. Cox
Cancer Res March 1 1996 (56) (5) 1131-1136;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Interleukin 12 Primes Macrophages for Nitric Oxide Production in Vivo and Restores Depressed Nitric Oxide Production by Macrophages from Tumor-bearing Mice: Implications for the Antitumor Activity of Interleukin 12 and/or Interleukin 2
Jon M. Wigginton, Douglas B. Kuhns, Timothy C. Back, Michael J. Brunda, Robert H. Wiltrout and George W. Cox
Cancer Res March 1 1996 (56) (5) 1131-1136;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract 6618: A database of potential T cell epitopes for cancer immunotherapy
  • Abstract 6694: Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models
  • Abstract 6630: Synergistic immuno photothermal nanotherapy (SYMPHONY) for combination cancer therapy
Show more Immunology

Articles

  • Introduction of H. Rodney Withers
  • Intersections between Blood Cell Development and Leukemia Genes
  • Id Gene Expression as a Key Mediator of Tumor Cell Biology
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement